Finanzen von Evolent Health Inc (EVH)EVHEvolent Health Inc

Evolent Health, Inc. (EVH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinical Solutions, accounting for 73.3% of total sales, equivalent to $507.48M. Other significant revenue streams include Evolent Health Services and Intersegment Eliminations. Understanding this composition is critical for investors evaluating how EVH navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Evolent Health, Inc. maintains a gross margin of 9.08%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.34%, while the net margin is -4.35%. These profitability ratios, combined with a Return on Equity (ROE) of -79.90%, provide a clear picture of how effectively EVH converts its operational activities into shareholder value.

In the context of the broader market, EVH competes directly with industry leaders such as HUYA and SBC. With a market capitalization of $534.77M, it holds a leading position in the sector. When comparing efficiency, EVH's gross margin of 9.08% stands against HUYA's 14.66% and SBC's 73.14%. Such benchmarking helps identify whether Evolent Health, Inc. is trading at a premium or discount relative to its financial performance.

Evolent Health has reported a gross margin of 9.08% in Q2 2026, down from previous quarters, indicating challenges in profitability. The forward P/E ratio is 8.62, suggesting that the stock may be undervalued relative to its earnings potential.